ArcticZymes AS, a subsidiary company of Biotec Pharmacon ASA, has received a grant of NOK 5 million from the The Research Council of Norway, for a project titled “Functionalization of enzymes from marine bioprospecting”. The total project budget is NOK approx. 10 million over 3 years. The project is a user driven innovation project which aims to accelerate the commercialization …
ArcticZymes Signs Enzyme Supply Agreement with New England Biolabs
ArcticZymes AS, the Tromsø-based manufacturer of innovative heat-labile molecular biology enzymes, has signed a supply agreement with New England Biolabs Inc. (NEB) for the supply of Recombinant Shrimp Alkaline Phosphatase (SAP) from ArcticZymes. NEB plans to offer SAP through its global distribution network. The agreement also allows for the introduction of other ArcticZymes’ products through NEB at a later date. …
ArcticZymes strengthens its Sales and Marketing force
ArcticZymes® is pleased to announce the hiring of Mr. Dino DiCamillo in a temporary position as worldwide Director of Sales and Marketing. DiCamillo has more than 30 years experience as a commercial and operational leader in the research and diagnostic industry and a proven track record in business development, key account strategy and management, OEM sales, and end-user marketing activities. …
SAP Patent Family Entirely Approved
ArcticZymes AS finalizes its protection of the SAP patent family ArcticZymes AS, a subsidiary of Biotec Pharmacon ASA (TICKER: BIOTEC) has received a Notice of Allowance for the Norwegian patent application of the SAP-patent family. The allowed patent covers the product and its use as well as the method of producing SAP, ArcticZymes’ top-selling enzyme Shrimp Alkaline Phosphatase (SAP). With …